Unaltered oncological outcomes of radical cystectomy with extended lymphadenectomy over three decades

Zehnder, Pascal; Studer, Urs E.; Skinner, Eila C.; Thalmann, George N.; Miranda, Gus; Roth, Beat; Cai, Jie; Birkhäuser, Frédéric D.; Mitra, Anirban P.; Burkhard, Fiona C.; Dorin, Ryan P.; Daneshmand, Siamak; Skinner, Donald G.; Gill, Inderbir S. (2013). Unaltered oncological outcomes of radical cystectomy with extended lymphadenectomy over three decades. BJU international, 112(2), E51-E58. Blackwell Science 10.1111/bju.12215

Text Zehnder_BJU Int_2013_112_E51.pdf - Published Version Restricted to registered users only Available under License Publisher holds Copyright. Download (375kB) | Request a copy

OBJECTIVE To evaluate oncological outcome trends over the last three decades in patients after radical cystectomy (RC) and extended pelvic lymph node (LN) dissection. PATIENTS AND METHODS Retrospective analysis of the University of Southern California (USC) RC cohort of patients (1488 patients) operated with intent to cure from 1980 to 2005 for biopsy confirmed muscle-invasive urothelial bladder cancer. To focus on outcomes of unexpected (cN0M0) LN-positive patients, the USC subset was extended with unexpected LN-positive patients from the University of Berne (UB) (combined subgroup 521 patients). Patients were grouped and compared according to decade of surgery (1980-1989/1990-1999/≥2000). Survival probabilities were calculated with Kaplan-Meier plots, log-rank tests compared outcomes according to decade of surgery, followed by multivariable verification. RESULTS The 10-year recurrence-free survival was 78-80% in patients with organ-confined, LN-negative disease, 53-60% in patients with extravesical, yet LN-negative disease and ≈30% in LN-positive patients. Although the number of patients receiving systemic chemotherapy increased, no survival improvement was noted in either the entire USC cohort, or in the combined LN-positive USC-UB cohort. In contrast, patient age at surgery increased progressively, suggesting a relative survival benefit. CONCLUSIONS Radical surgery remains the mainstay of therapy for muscle-invasive bladder cancer. Yet, our study reveals predictable outcomes but no survival improvement in patients undergoing RC over the last three decades. Any future survival improvements are likely to result from more effective systemic treatments and/or earlier detection of the disease.

Interest & Impact

Downloads

13 since deposited on 04 Jun 2014
0 in the past 12 months

Citations

5 Citations in Web of Science ®
6 Citations in Scopus

Search

in Google Scholar™

Services

Actions (login required)

Edit item

Actions (login required)

Edit item